**Medical Science** 



Correlation of Q T and P Wave Dispersion to Ventilatory

# Functions in COPD Patients

Dr. Prashila P Shende		Lecturer, Department of Physiology, B J Medical, College, Pune. State- Maharashtra.			
Dr. Sangeeta M Gawali		Associate Professor, Department of Physiology, B J Medical, College, Pune. State- Maharashtra.			
ABSTRACT	million people in India. F sudden cardiac death of Method: 50 diagnosed ECG was recorded usin Helios Spirometer (RMS Correlation was done by Observations and Results control group and there Conclusion: Prolonged Q	ostructive pulmonary disease (COPD) is the fourth leading cause of death, affects more than 2.7 Patients with COPD also carry an increased risk of mortality due to tachyarrhythmia and due to prolonged QT and P wave dispersion. COPD patients of chronic bronchitis and emphysema was compared with 50 healthy control. ng Clarity Med ECG 50-1 CH. and pulmonary function tests were performed with 702 is, India). ECG parameters and pulmonary function tests were compared by using unpaired 't' test. Pearson's co-relation coefficient and p value was calculated. St QT & P wave dispersion is found to be prolonged in COPD patients compared to healthy e was negative correlation of QT and P wave dispersion with various spirometric parameters. T dispersion in COPD patients is associated with generation of life threatening rhythm disturbances in. There is Intriguing relationship between the QT dispersion and functional respiratory parameters.			

**Research Paper** 

KEYWORDS QT di	ispersion, P	wave d
----------------	--------------	--------

QT dispersion, P wave dispersion, chronic obstructive pulmonary disease.

#### INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) is highly prevalent disease affecting lungs as well as cardiovascular system. COPD refers to a spectrum of disease characterized by cough, sputum production, dyspnoea, air flow limitation and impaired gas exchange. Smoking, exposure to biomass smoke, indoor & outdoor pollution, occupational exposure to dust & gases are the common causes of COPD. <sup>(1)</sup>

The lung health study showed that substantial proportion of deaths in patients with mild COPD was the result of the cardiovascular complications.<sup>(2)</sup> The spectrum of cardiovascular diseases in COPD includes pulmonary hypertension and cor pulmonalae i.e. Right ventricular hypertrophy, P pulmonalae, Right axis deviation and Right bundle branch block.<sup>(3)</sup> Patients with COPD also carry an increased risk of mortality due to tachyarrhythmia & sudden cardiac death compare with those who do not.<sup>(4)</sup> However COPD patients are not usually assessed by ECG in routine medical practice particularly in developing countries like India. Various electrocardiographic changes have been described in patients with COPD.

QT dispersion (QTd) & P wave dispersion (Pd) calculated from 12 lead ECG have been proposed as non invasive predictors of cardiac arrhythmias & atria fibrillation that occurs in patients with COPD respectively.<sup>(5)</sup>

Pathogenesis of tachyarrhythmia in COPD patients is multifactorial and includes a number of risk factors such as hypoxemia, acidosis & reduced FEV1.<sup>(5)</sup>

Present study was conducted to evaluate ECG derived indices like QT interval, QT dispersion, P wave dispersion in COPD patients and also to correlate these ECG parameters with spirometric parameters like FEV1, FEV1/FVC, FEF(25-75).

#### MATERIAL AND METHOD

Present study was conducted in outpatient department of Sasoon general Hospital, Pune. Written informed consent of subjects and Ethical committee approval was taken. Study design: cross sectional comparative study.

**Study type**: comparative and correlative.

**Study group** : Fifty diagnosed COPD patients (both male and female) 35-70 yrs, of chronic bronchitis and emphysema were selected. Diagnosis is done according to GOLD criteria ( $FEV_1 < 80\% \& FEV_1/FVC < 70\%$ ) after taking bronchodilator therapy.

**Control** group: 50 healthy control of same age and sex.

**Exclusion criteria** : Diabetes, Hypertension, LVH, IHD, Obesity (BMI < 24.9 kg/m<sup>2</sup>).

**Data collection**: Vital parameters like Pulse rate , Blood Pressure was recorded in supine position. BMI was calculated by using formula.

#### BMI = Weight in Kg / (Height in meters).

ECG was recorded using **Clarity Med ECG 50-1 CH**. Participants were instructed not to smoke or consume alcohol, tea, coffee or to engage in strenuous physical activity 12 hours prior to ECG recording. 12 lead ECG was taken after 10 minutes of rest in supine position at the same time of the day (10 a.m.-1p.m.)

Following ECG derived indices were measured.

- (1) **QT interval (QT)** :- Time interval between beginning of Q wave to the end of T wave i.e reaching to baseline in all 12 leads, measured manually and average of 3 readings was taken.<sup>(6)</sup>
- (2) Corrected QT interval (QTc) <sup>(7)</sup>: √ ulated manually by Bazett's Formula : QTc =QT/ √ RR. QTc represents the QT interval corrected for heart rate.
- RR is calculated from the onset of one QRS complex to the onset of next QRS complex.
- (3) **QT dispersion (QTd)** <sup>(8)</sup> QT dispersion was calculated from the difference

between maximum & minimum QT interval.

- (4) P wave duration : The beginning of the P wave was defined as the point where the initial deflection of the P wave crossed the isoelectric line and the end of the P wave was defined as the point where the final deflection of the P wave crossed the isoelectric line.<sup>(9)</sup>
- (5) **P wave dispersion** : P wave dispersion was defined as the difference between maximum and minimum P wave duration.<sup>(9)</sup>

**SPIROMETRY:** The pulmonary function parameters were measured using a computerized portable **RMS Helios 702** (Chandigarh) spirometer. This spirometer is automated and has a flow sensor which converts the airflow signals to digital signals. Values obtained were in litres and they were compared with the existing data base for the normal healthy Indian population depending on age, sex, height and weight. The tests were conducted according to the American Thorac-ic Society<sup>(10)</sup> European Respiratory Society (ATS/ERS) task force guidelines.

**Procedure--** The pulmonary functions were recorded in the sitting position Name, age, sex, height and weight were entered in the spirometer.

Forced Vital Capacity (FVC) manoeuvre was conducted in the following order:

- 1) Subjects were instructed to hold the mouthpiece in the mouth with lips pursed around it.
- They were instructed to breathe normally through the mouthpiece.
- 3) After the three normal breaths, they were asked to take deep inspiration and asked to blow forcefully into the mouthpiece as long as possible without hesitation and coughing. Then without removing the mouthpiece from the mouth, they were instructed to inspire maximally through the mouthpiece following Parameters recorded and expressed as predicted value and test value.

a.Force expiratory volume in one second (FEV<sub>1</sub>) in litres. b.FEV /FVC in %.

### c. FEF(25-75)

#### STATISTICAL ANALYSIS

All variables are expressed as mean + SD. ECG parameters and pulmonary function tests were compared by using unpaired 't' test in COPD patients and control. Correlation of QTd and Pd with pulmonary function parameters was done by Pearson's correlation coefficient and P value was calculated. The level of statistical significance in each case was taken as P<0.0

#### RESULTS

**Table 1** Shows comparison of age (59.16  $\pm$  4.26 vs. 59.24  $\pm$  4.78, p>0.05) and BMI (19.68  $\pm$  4.76 vs. 20.41  $\pm$  3.84, p>0.05) in COPD and control group respectively. BMI is within normal range (18.5 - 24.9 kg/m<sup>2</sup>).which rule out obesity. Both groups were comparable with respect to age and BMI. Systolic blood pressure (143.2  $\pm$  4.9 vs 119.72  $\pm$  8.01, p<0.0001), Diastolic blood Pressure (92.84  $\pm$  2.9 vs 75.68  $\pm$  4.68, p<0.0001), and Heart Rate (126.62  $\pm$  5.02 vs 81.26  $\pm$  5.31, p<0.0001) is more in COPD patients compared to control group.

**Table 2** Shows decreased QT interval in COPD patients (302.8  $\pm$  8.18 vs 322.72  $\pm$  25.99, p<0.001) as compared to control group. Increased resting heart rate which affect QT interval but after correction with heart rate by **Bazett's formula** <sup>(17)</sup> corrected QT interval (QTc) is more in COPD patients (431.7  $\pm$  26.6 vs 384.24  $\pm$  33, p<0.0001) as compared to control group . **QT dispersion (QTd) is found to be significantly increased in COPD patients (65.2 \pm 4.5 vs 37.34 \pm 5.33, P value <0.0001) as compared to control group. Table No. 2 also shows prolonged P wave duration (115.2 \pm 8.62 vs. 90.2 \pm 12.53, P <0.0001) and prolonged P wave dispersion (43 \pm 12.16 vs. 37.2 \pm 8.09, p<0.05) in COPD patients** 

tients compared to control group

**Table No 3** Shows significantly reduced spirometric parameters i.e.FEV<sub>1</sub> (1.80 ± 0.69 vs 2.63 ± 0.46, p<0.0001), FEV<sub>1</sub>/FVC (77.06 ± 6.97 vs 88.18 ± 5.73, p<0.01) and FEF<sub>25.75</sub> (2.78 ± 0.59 vs 3.33 ± 0.90, p<0.05) in COPD patients compared to Control group respectively.

**Table No.4** Shows positive correlation of QT dispersion with Heart Rate (r = 0.888, p < 0.0001), Systolic Blood Pressure (r = 0.670, p < 0.0001) and Diastolic Blood Pressure(r = 0.969, p < 0.0001) in COPD patients as compared to control.

**Table No.5** Shows positive correlation of QT dispersion with various spirometric parameters like FEV<sub>1</sub> (r = -0.874, p<0.0001), FEV<sub>1</sub>/FVC (r = -0.903, p<0.0001) and FEF<sub>(25-75)</sub>(r = -0.715, p<0.0001) in COPD patients and there was no correlation of

QT dispersion with FEV, (r = -0.058, p>0.05), FEV,/FVC (r = -0.178, p>0.05) and FEF\_{\_{(25-75)}} ( r = -0.066, p >0.05) in control group.

**Table No 6** Shows there is no correlation of P wave dispersion with any cardiac parameters like Heart Rate (r = 0.163, p>0.05), Systolic blood pressure (r = 0.095, p>0.05) and Diastolic blood pressure (r = 0.227, p>0.05) in COPD patients compared to control group.

**Table No.7** P wave dispersion is not correlated with spirometric parameters like FEV<sub>1</sub> (r = -0.202, p > 0.05), FEV<sub>1</sub>/FVC (r = -0.156, P > 0.05) in COPD patients. but there is positive correlation of P wave dispersion with FEF<sub>(25-75)</sub> (r = -0.455 P<0.005) in COPD patients compared to control group (r = 0.145, p > 0.05).

#### DISCUSSION

In the present study, we evaluated ECG derived indices like QT interval, corrected QT interval, QT dispersion, P wave duration and P wave dispersion in 50 COPD patients and 50 age and sex matched Control. QT dispersion and P wave dispersion was correlated with following parameters between COPD and control group.

- 1. Age, BMI, Heart Rate, Systolic and Diastolic blood pressure.
- 2. Spirometric parameters like FEV, FEV, FEV, FEF (25-75).

The present study shows following statistically significant findings which need to be addressed

- 1. QT dispersion (QTd) is found to be significantly increase in COPD patients ( $65.2 \pm 4.5$  vs  $37.34 \pm 5.33$ , P value <0.0001) as compared to control group.
- Prolonged P wave duration (115.2 ± 8.62 vs. 90.2 ± 12.53, P <0.0001) and prolonged P wave dispersion (43 ± 12.16 vs. 37.2 ± 8.09, p<0.05) in COPD patients compared to control group.
- Positive correlation of QTd with various spirometric parameters FEV<sub>1</sub>, FEV<sub>1</sub>/FVC and FEF<sub>(25-75)</sub>.
  Positive correlation of P wave dispersion with FEF<sub>(25-75)</sub> (r
- Positive correlation of P wave dispersion with FEF (25-75) (r = - 0.455 P<0.005) in COPD patients compared to control group (r = 0.145, p>0.05).

#### Increased QTd in COPD patients.

Previous study by **Pinar Yildiz**<sup>(5)</sup> et al have shown that development of ventricular arrhythmia in COPD patients is associated with QT dispersion. Our results are comparable with their study. **Niranjan Mambally Rachaiah**<sup>(11)</sup> et al studied 108 patients of COPD and showed positive correlation between ECG changes and pulmonary function parameter.

Several explanations have been put forward to explain increased QTd in COPD patients.

1) Hypoxia in COPD patients increase myocardial O demand

and Adversely affects left ventricular performance, which may alter QT dispersion.  $^{\left( 12\right) }$ 

- Hypoxia increases phase 4 depolarization of myocardial muscles and also increases rate of spontaneous depolarization in conducting tissues of heart leads to vulnerable development of tachyarrhythmias. <sup>(13)</sup>
- Flick & Block found that cardiac arrhythmias were at their maximum when arterial oxygen saturation is at its lowest and oxygen therapy ameliorate these arrhythmias. <sup>(14)</sup>
- Autonomic Nervous System directly affects QT interval. Autonomic tone may affect corrected QT interval and QT dispersion through depolarization and repolarization kinetics of myocardial cells. <sup>(15)</sup>
- 5). QT dispersion has been reported to be prolonged in patients with primary autonomic failure. <sup>(15)</sup>.

#### Prolonged P wave duration and prolonged P wave dispersion in COPD patients

Previous study done by **Hekim karapinar** <sup>(16)</sup> shown that prolonged P wave dispersion is an ECG marker that reflects discontinuous and inhomogeneous conduction of sinus impulses. <sup>(16)</sup> Therefore such patients are more prone to carry an increased risk for atrial fibrillation. <sup>(16)</sup> They also proposed that P wave duration and P wave dispersion is influenced by the autonomic tone, which induce changes in the velocity of impulse propagation. <sup>(16)</sup> Our results are also comparable with previous study.

Cardiac arrhythmia and sudden death are common and important causes of mortality in COPD patients. <sup>(5)</sup> Prolonged QT dispersion is an indication of inhomogeneous ventricular repolarization phase responsible for developing tachyarrhythmias & sudden cardiac death.<sup>(5)</sup> So, the present study shows that COPD patients are prone to develop tachyarrhythmias & sudden cardiac death due to prolonged QT dispersion and also prone to develop atrial fibrillation due to prolonged P wave duration & P wave dispersion compared to control group.

## Positive correlation of QTd with various spirometric parameters FEV,, FEV,/FVC and FEF (25.75).

**rameters FLV**, **FEV**, **/FV**, **and FEF** (25-75). In COPD patients decreased FEV<sub>1</sub>, FEV<sub>1</sub>/FVC and FEF (25-75) is responsible for prolongation of QT dispersion suggesting that hypoxia, hypercapnia due to airway obstruction may influence ventricular repolarization which is responsible for prolongation of QT dispersion.<sup>(13,14)</sup>

## Positive correlation of P wave dispersion with FEF in COPD patients.

FEF  $_{(25-75)}$  is a sensitive index of obstructive pathology.<sup>(17)</sup> Chronic airway obstruction may affect conduction of sinus node responsible for arrhythmias like atrial fibrillation

From above discussion, it appears that in COPD patients, chronic airway obstruction affect cardiovascular system leading to increased Heart Rate, Systolic Blood pressure, Diastolic Blood pressure. It is due to increased myocardial oxygen demand and workload.<sup>(18)</sup> In due course it affects electrophysiological parameters like QT Interval, QT dispersion, P wave duration, P wave dispersion leading to prolonged QT dispersion and ventricular arrhythmia. Chronic airway obstruction may affect conduction of sinus node responsible for arrhythmias like atrial fibrillation.

#### CONCLUSION

- 1) Prolonged QT dispersion in COPD is associated with generation of life threatening rhythm disturbances and sudden cardiac death.
- QT dispersion, is a non invasive marker of arrhythmogenicity so,analysis of routine ECG is an important, non invasive, inexpensive, bedside, diagnostic
  - tool to detect early arrhythmias in COPD patients.
- 3). There is Intriguing relationships between the QT dispersion and functional respiratory parameters.
- Greater the severity of COPD, greater will be the prolongation of QT dispersion.
- 5) We recommend that, all COPD patients should undergo

These findings suggest the need for a global and multidisciplinary risk assessment in COPD patients. Therefore, special attention in the diagnostic work-up of these patients is needed, coming to a more integrated pulmonary and cardiovascular care.

**Acknowledgements:** Authors acknowledge the immense help received from the scholars whose articles are cited & included in references of this manuscript. The authors are grateful to all the staff that have contributed & cooperated in the study. And are also thankful to the Department of Physiology, Department of Chest & TB, B J M C Pune for providing the requisite infrastructure for the study.

Table 1: Shows mean values of Age, BMI, Heart Rate , Systolic & Diasolic Blood Pressure.

Dawawastawa	COPD (n=50)	control (n=50)	4 <b>.</b>	p value	
Parameters	$\textbf{Mean} \pm \textbf{SD}$	Mean ± SD	t value		
Age (yrs)	59.16 ± 4.26	59.24 ± 4.78	0.06	>0.05	
BMI (kg/m <sup>2)</sup>	19.68 ± 4.76	20.41 ± 3.84	0.6	>0.05	
Systolic BP (mm of Hg)	143.2 ± 4.9	119.72 ± 8.01	12.46	0.0001**	
Diastolic BP (mm of Hg)	92.84 ± 2.9	75.68 ± 4.68	15.15	<0.0001**	
Heart Rate (bpm)	126.62 ± 5.02	81.26 ± 5.31	31	0.0001**	

Table 2: Shows mean values of QT Interval, corrected QT Interval, QT dispersion P wave duration and P wave dispersion in COPD patients and control group.

Parameters.	COPD	control	t value	p value
QT Interval (ms)	302.8 ± 8.18	322.72 ± 25.99	3.65	<0.001**
QTc Interval (ms)	431.7 ± 26.6	384.24 ± 33.00	5.59	<0.0001**
QT dispersion (ms)	65.2 ± 4.5	37.34 ± 5.33	19.84	<0.0001**
P wave duratio(ms)	115.2 ± 8.62	90.2 ± 12.53	8.21	<0.0001**
P wave dispersion.	43 ±12.16	37.2 ± 8.09	1.99	<0.05*

Table 3 : Shows mean values of  $FEV_1$ ,  $FEV_1/FVC \& FEF_{(25.75V)}$  in COPD Pt. & control group.


/5)*		5 1		
Parameters	COPD	control	t value	p value
1 1		2.63 ± 0.46	4.02	<0.0001**
FEV <sub>1</sub> /FVC (%)	77.06 ± 6.97	88.18 ± 5.73	6.16	<0.0001**
FEF <sub>25-75</sub> (L/ sec)	2.78 ± 0.59	3.33 ± 0.90	2.53	<0.05*


Table 4: Shows correlation of QT dispersion with age, BMI, Heart Rate, Systolic and Diastolic Blood pressure in COPD patients and control group.

	COPD		control	
Parameters	r value	p value	r value	p value
A Age (Yrs)	-0.240	>0.05	-0.268	>0.05
B BMI (Kg/m <sup>2</sup> )	0.201	>0.05	0.139	>0.05
H Heart Rate (bpm)	0.888	<0.0001**	-0.169	>0.05
S Systolic BP (mmHg)	0.670	<0.0001**	-0.264	>0.05
D Diastolic BP (mmHg)	0.969	<0.0001**	-0.115	>0.05

Table 5: Shows correlation between QT dispersion and spirometric parameters in COPD patients and control group.

Daramators	COPD		control	
Parameters	r Value	p Value	r value	p value
FEV <sub>1</sub> (Litres)	-0.874	<0.0001**	-0.058	>0.05
FEV <sub>1</sub> /FVC (%)		<0.0001**		>0.05
FEF <sub>(25-75)</sub> (L/sec)		<0.0001**		>0.05








Table 6: Shows correlation between P wave dispersion and age, BMI, Heart Rate,Systolic and Diastolic Blood pressure in COPD patients and control group.

Parameters	COPD		control	
	r Value	p Value	r value	p value
Age (Yrs)	0.010	>0.05	0.039	>0.05
BMI (Kg/m <sup>2</sup> )	0.099	>0.05	0.128	>0.05
Heart Rate (bpm)	0.163	>0.05	0.027	>0.05
S Systolic BP (mmHg)	0.095	>0.05	0.114	>0.05
D Diastolic BP (mmHg)	0.227	>0.05	-0.089	>0.05

## Table 7: Shows correlation between P wave dispersion and spirometric parameters in COPD and control group.

				• •
Parameters	COPD	COPD		
Farameters	r value	p value	r value	p value
FEV <sub>1</sub> (Litres)	-0.202	>0.05	0.112	>0.05
FEV,/FVC (%)	-0.156	>0.05	0.085	>0.05
FEF(25.75) (L/sec)	-0.455	<0.005*	0.145	>0.05

#### **Reference :**

- Reilly JJ, Jr, Silverman E K, Shapiro S D. Chronic obstructive pulmonary disease. Harrison's, Principles of Internal Medicine. 18 th Edition. Mc Graw Hill; Volume I, 2012; Pg 2151-59.
- Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Eng J Med. 2000;343:1902–9.
- Warnier MJ, Rutten FH, Numans ME, Kors JA, Tan HL, Anthonius de B.et al. Electrocardiographic Characteristics of Patients with Chronic Obstructive Pulmonary Disease. COPD 2013; 10:62-71
- Burrows B, Kettel L J, Niden A H, Rabinowitz M, Diener CF. Patterns of Cardiovascular Dysfunction in Chronic Obstructive Lung Disease. N Engl J Med 1972; 286 : 912–8.
- Yildiz P, Tu'kek T, Akkaya V, So'zen AB, Yildiz A, Korkut F et al Ventricular arrhythmias in patients with COPD are associated with QT dispersion. *Chest* 2002;122(6):2055–61.
- 6) Barret KE, Barman SM, Boitano S, Brooks HL.Origin Of The Heart Beat And The Electrical Activity Of The Heart. Ganong's Review of Medical Physiology. 23<sup>rd</sup> edition, Tata Mcgraw Hill 2010; p.310-11.
- Bazett HC. An analysis of the time relations of electrocardiograms. *Heart* 1920; 7:353-70.
- Malik M, Batchvarov VN. Measurement, interpretation and clinical potential of QT dispersion. J Am Coll Cardiol 2000; 36:1749.
- Gunduz H, Binak E, Arinc H, Akdemir R, Ozhan H, Tamer A. et al The Relationship between P Wave Dispersion and Diastolic Dysfunction. *Tex Heart Inst J.* 2005; 32(2): 163–7.
- ATS/ERS task force: Standardization of lung function testing. Standardization of spirometry. *Eur. Respir J* 2005;26:319-38.
- Rachaiah N M, Rachaiah J M, Krishnaswamy R. A correlative study of spirometric parameters and ECG changes in patients with chronic obstructive pulmonary disease. *Int J Biol Med Res.* 2012; 3(1): 1322-26.
- Singh K. Effect of smoking on QT interval, QT dispersion and rate pressure product. Indian Heart Journal 2004; 56(2):140-42.
- Tirlapur V G, Mir. Nocturnal Hypoxemia and Associated Electrocardiographic Changes in Patients with Chronic Obstructive Airways Disease. N Engl J Med 1982; 306:125-130.
- 14) Flick MR, Block AJ. Nocturnal vs diurnal cardiac arrhythmias in patients with chronic obstructive pulmonary disease. *Chest* 1979;(75) :8-11.
- Lo SS Mathias, C J Sutton, M S. QT interval and dispersion in primary autonomic failure. *Heart (British Cardiac Society)*. May 1996; 75 (5): 498–501.
- 16) Karapinar H, Esen O, Bulut M, Pala S, Akçakoyun M, Kargin R et al. Effect of habitual cigarette smoking, on P wave duration and dispersion. 2010;13(3):10-13
- 17) Sreenivas S B, Sunitha M S, Nataraj S M, And Murali Dhar. A Study Of Deterioration Of Pulmonary Function Parameters Among Smokers And Recovery Among Ex-Smokers In Bus Depot Workers. *Indian J Physiol Pharmacol.* 2012; 56(2) 154–160
- Padrid PJ, Fuchs T, Candinas R. Role of sympathetic nervous system in the genesis of ventricular arrhythmia. *Circulation*. 1990; 82: 103-13